Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 20, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 5,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,070.18 pence per share.
- Total Cost: Approximately £53.5 million (calculated from share count and price).
Material Changes
Following the cancellation of the repurchased shares, the company's capital structure has changed as follows:
- Treasury Shares: The Company now holds 504,194,158 shares in Treasury, representing 9.30% of the total voting rights.
- Shares in Issue: There are 5,423,697,937 shares in issue (excluding Treasury shares), which represents the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total voting rights denominator (5,423,697,937 shares) for compliance with disclosure thresholds.
- Confirm the impact of the 5,000,000 share cancellation on the company's total share count and Treasury holdings.
- Note that this filing does not contain operational or financial performance data for the period; refer to Form 20-F for full financial results.